+

US5576331A - Agent for preventing and treating disturbances of intestinal mucous membrane - Google Patents

Agent for preventing and treating disturbances of intestinal mucous membrane Download PDF

Info

Publication number
US5576331A
US5576331A US08/256,372 US25637294A US5576331A US 5576331 A US5576331 A US 5576331A US 25637294 A US25637294 A US 25637294A US 5576331 A US5576331 A US 5576331A
Authority
US
United States
Prior art keywords
mucous membrane
preventing
disturbances
intestinal
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/256,372
Inventor
Katsuya Yamasaki
Kazushi Sakurai
Kazue Akiyama
Toshihiro Osaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Assigned to OTSUKA PHARMACEUTICAL CO., LTD. reassignment OTSUKA PHARMACEUTICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AKIYAMA, KAZUE, SAKURAI, KAZUSHI, YAMASAKI, KATSUYA
Application granted granted Critical
Publication of US5576331A publication Critical patent/US5576331A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Definitions

  • the present invention relates to an agent for preventing and treating disturbances of intestinal mucous membrane. More particularly, the present invention relates to an agent for preventing and treating disturbances of intestinal mucous membrane, comprising, as the active ingredient, a carbostyril derivative represented by the following general formula (I): ##STR1## (wherein, R is a halogen-atom (a fluorine atom, a chlorine atom, a bromine atom or an iodine atom); the substituent on the carbostyril skeleton is at the 3- or 4-position of the carbostyril skeleton; and the bond between the 3- and 4-positions of the carbostyril skeleton is a single bond or a double bond) or a salt thereof, preferably 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid or a salt thereof.
  • R is a halogen-atom (a fluorine atom, a chlorine atom, a
  • the carbostyril derivatives represented by the above general formula (I) and the processes for production of said derivatives are described in Japanese Patent Publication No. 63-35623, etc. and the utility of said derivatives as an inhibitor for gastric ulcer is known. Further, the utility of the derivatives as a gastritis-treating agent is described in Japanese Patent Application Kokai (Laid-Open) No. 3-74329, and the processes for producing those compounds of said derivatives having an optical activity are described in Japanese Patent Application Kokai (Laid-Open) No. 3-145468.
  • Disturbances of intestinal mucous membrane include simple and primary ulcer of small intestine, nonspecific ulcer of colon, ulcerative colitis induced by nonspecific inflammations, Crohn's disease, etc., all of which appear owing to unknown causes. Disturbances of intestinal mucous membrane also appear owing to known causes such as infections, circular disturbances, collagen disease, radiations, medicines and the like. These disturbances of intestinal mucous membrane are generally hard to cure and, in some cases, surgical treatments are applied thereto. As the medicinal therapy for the disturbances, there are used adrenocortical steroids, Salazopyrin, immunosuppressive agents, etc.
  • the steroidal drugs show side effects when administered in a large amount over a long period of time, and the immunosuppressive agents must be carefully used because of the very harmful side effects.
  • Nonsteroidal anti-inflammatory drugs which are widely used for various diseases attended by inflammations such as arthritis, chronic rheumatoid arthritis and the like, are known to give rise to disturbances of intestinal mucous membrane. The administration of these drugs must therefore be stopped in the middle in some cases. In patients of chronic rheumatoid arthritis, the treatment of rheumatism must be continued even when disturbances of intestinal mucous membrane have appeared, which requires the continued use of NSAID in such cases and poses a problem.
  • the present inventors made an extensive study in order to find out a novel drug useful for prevention and treatment of disturbances of intestinal mucous membrane.
  • the present inventors found that the carbostyril derivatives represented by the above general formula (I) or salts thereof, in particular, 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid or a salt thereof is useful for the prevention and treatment of disturbances of intestinal mucous membrane which are hard to cure.
  • the finding has led to the completion of the present invention.
  • the present agent for preventing and treating disturbances of intestinal mucous membrane when used by itself, is prepared in any form of ordinary pharmaceutical preparations each comprising a carbostyril derivative of general formula (I) or a salt thereof.
  • Such preparations are prepared using diluents or excipients ordinarily employed, such as filler, extender, binder, wetting agent, disintegrating agent, surfactant, lubricant and the like.
  • the pharmaceutical preparations can take various forms depending upon how they are administered for treatment, and typical examples of the forms are tablets, pills, a powder, a liquor, a suspension, an emulsion, granules, capsules, suppositories and injection preparations (solution, suspension, etc.).
  • excipients such as lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicic acid and the like; binders such as water, ethanol, propanel, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose, shellac, methyl cellulose, calcium phosphate, polyvinyl pyrrolidone and the like; disintegrating agents such as dried starch, sodium alginate, agar powder, laminalia powder, sodium hydrogencarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, monoglyceride of stearic acid, starch, lactose and the like; disintegration inhibitors such as sucrose, stearin, coconut butter, hydrogenated oil and the like; absorption accelerators such as quaternary ammoni
  • known carriers widely used in this field can be used. They are exemplified by excipients such as glucose, lactose, starch, coconut butter, hydrogenated vegetable oil, kaolin, talc and the like; binders such as powdered gum arabic, powdered tragacanth gum, gelatin, ethanol and the like; and disintegrating agents such as laminaria, agar and the like.
  • known carriers widely used in this field can be used. They are exemplified by polyethylene glycol, coconut butter, higher alcohols, higher alcohol esters, gelatin and semi-synthetic glycerides.
  • solutions, emulsions or suspensions are prepared and are generally further sterilized and preferably made isotonic to the blood.
  • any known carrier widely used in this field can be used. It is exemplified by water, ethanol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol and polyoxyethylene sorbitan fatty acid esters.
  • the solutions, emulsions or suspensions may further contain sodium chloride, glucose or glycerine in an amount sufficient to make them isotonic to the blood.
  • the solutions, emulsions or suspensions may furthermore contain a dissolving agent, a buffer solution, an analgesic agent, etc. all of ordinary use and, as necessary, a coloring agent, a preservative, a perfume, a seasoning agent, a sweetening agent and other medicines.
  • the two medicines may be administered as different medicines or as a mixed agent containing the two medicines.
  • the NSAID's with which the present agent is used in combination are not particularly restricted and include all NSAID's widely used, such as Aspirin, Indomethacin, Diclofenac, Ibuprofen, Naproxen, Piroxicam, Mefenamic Acid, Flufenamic Acid, Floctafenine, Ethenzamide, Sodium salicylate, Diflunisal, Clofezone, Ketophenylbutazone, Phenylbutazone, Alclofenac, Alminoprofen, Ketoprofen, Flurbiprofen, Pranoprofen, Loxoprofen-Na, Tiaramide hydrochloride, Perisoxal citrate, Emorfazone, Acemetacin, Proglumetacin maleate, Bucolome and the like.
  • the amount of the present agent administered is appropriately determined depending upon the administration method, the age, sex and other conditions of patient, the degree of disease, etc. However, the preferable amount is generally 0.6-50 mg per kg of body weight per day in terms of the amount of carbostyril derivative of general formula (I) or salt thereof.
  • the preferable amount of active ingredient in each application unit form is 10-1,000 mg when used in combination with NSAID.
  • the present agent, when used in combination with NSAID is used in an amount of generally 0.1-100 parts by weight per 1 part by weight of NSAID although the amount differs depending upon the kind of the NSAID used in combination.
  • each administration unit form generally contains 10-1,000 mg of a carbostyril derivative of general formula (I) or a salt thereof and 1-1,000 mg of NSAID.
  • the amount of the carbostyril derivative of general formula (I) or the salt thereof contained in the present agent for preventing and treating disturbances of intestinal mucous membrane is not particularly restricted and can be selected from a wide range. However, the amount is generally 10-70% by weight, preferably, 10-50% by weight based on the total composition.
  • the present agent is used as a mixed agent containing both the present agent and NSAID
  • the total amount of the carbostyril derivative (I) or the salt thereof and NSAID is 10-90% by weight, preferably 30-70% by weight based on the total composition.
  • the present agent for preventing and treating disturbances of intestinal mucous membrane is useful for intractable disturbances of intestinal mucous membrane, particularly, ulcerative colitis and drug-induced disturbances of intestinal mucous membrane.
  • the present agent for preventing and treating disturbances of intestinal mucous membrane is described specifically by showing examples of pharmaceutical preparations as well as pharmacological tests.
  • the compound of the present invention [2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid], Avicel, corn starch and magnesium stearate are mixed and ground.
  • the mixture is shaped into tablets by using a punch having a diameter of 10 mm.
  • the tablets are coated with a film coating agent consisting of hydroxypropylmethyl cellulose, polyethylene glycol 6000, castor oil and methanol to prepare film-coated tablets.
  • the compound of the present invention [2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid], citric acid, lactose, calcium secondary phosphate, Pluronic F-68 and sodium lauryl sulfate are mixed.
  • the mixture is sieved through a No. 60 screen and then made into wet granules by using an alcholic solution containing polyvinylpyrrolidone, Carbowax 1500 and Carbowax 6000. As necessary, ethanol is added to make the granules into a paste-like semi-solid. Corn starch is added thereto and the mixture is kneaded until granules of uniform size are formed.
  • the granules are passed through a No. 10 screen, placed in a tray, and dried in an oven of 100° C. for 12-14 hours. The dried granules are sieved through a No. 16 screen.
  • the granules which have passed through the screen are mixed with dried sodium lauryl sulfate and dried magnesium stearate. The mixture is compressed into a desired shape by using a tablet machine.
  • the thus obtained tablets are treated with a varnish at the surfaces.
  • the varnish-treated surfaces are coated with talc so as to protect the surfaces from moisture absorption.
  • Thereon is applied undercoating.
  • Varnish coating is conducted sufficient times for oral administration.
  • Undercoating and smooth coating are further applied to make the tablets completely spherical and smooth.
  • Color coating is applied until a desired color is obtained.
  • the resulting coated tablets are dried and then their surfaces are polished to obtain multi-layer tablets of uniform gloss.
  • each rat was feeded as usual. 24 hours after operation, each rat was killed and the large intestine was extracted. The large intestine was cut longitudinally, opened and washed with a physiological saline solution to remove the contents, after which the washed large intestine was extended in a flat state. The lesion appearing in the mucous membrane of large intestine was observed by the naked eye and rated according to the following rating scale.
  • test compound dissolved in a solvent (a 0.5% carboxymethylcellulose aqueous solution) was orally administered twice a day (right after the acetic acid injection and 8 hours thereafter).
  • solvent a 0.5% carboxymethylcellulose aqueous solution
  • Grade 2 hyperemia, or linear ulcer attended by no hypertrophy of intestinal wall.
  • Grade 3 linear ulcer attended by inflammation.
  • Grade 4 ulcer attended by two or more inflammations.
  • Grade 5 ulcer attended by two or more large inflammations, or one large lesion of at least 1 cm in size extending in the longitudinal direction of large intestine.
  • Grades 6 to 10 when the size of ulcer attended by inflammation exceeds 2 cm in the longitudinal direction of colon, grade increases by one (for example, from 6 to 7) per each 1 cm increase of said size.
  • grade data are shown in the form of average value ⁇ standard error. Test of significance was conducted by non-parametric Dunnett type multiple comparison.
  • each rat male Wistar rat
  • an NSAID of an amount showing an analgesic effect [Aspirin (75 mg/kg), Ibuprofen (20 mg/kg), Naproxen (3 mg/kg) or Piroxicam (2 mg/kg)] and 30 mg/kg of a test compound [2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)-propionic acid]. They were administered twice a day for 1 week. Then, each rat was fasted for 24 hours and killed under anesthesia with ether, followed by extraction of alimentary canal from each rat.
  • the degrees of disturbances shown in Table 2 were rated using the following rating scale (grades 0 to (5) in accordance with the standard for rating of lesions of gastric mucosa by Adami et al. (Adami, E., et al.; Arch. int. Pharmacodyn. Ther., Vol. 147, Nos. 1-2, pp. 113-145, 1964).
  • Grade 3 5 or more small ulcers or one large ulcer.
  • Grade 4 many ulcers of marked size.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Quinoline Compounds (AREA)

Abstract

A method for preventing and treating disturbances of intestinal mucous membrane comprising administering to a patient in need thereof an effective amount of the compound 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl) propionic acid or a pharmaceutically acceptable salt thereof.

Description

This application was filed under 35 U.S.C. 371 from the application PCT/JP93/01700 filed Nov. 19, 1993.
This application was filed under 35 U.S.C. 371 from the application PCT/JP93/01700 filed Nov. 19, 1993.
BACKGROUND OF THE INVENTION
The present invention relates to an agent for preventing and treating disturbances of intestinal mucous membrane. More particularly, the present invention relates to an agent for preventing and treating disturbances of intestinal mucous membrane, comprising, as the active ingredient, a carbostyril derivative represented by the following general formula (I): ##STR1## (wherein, R is a halogen-atom (a fluorine atom, a chlorine atom, a bromine atom or an iodine atom); the substituent on the carbostyril skeleton is at the 3- or 4-position of the carbostyril skeleton; and the bond between the 3- and 4-positions of the carbostyril skeleton is a single bond or a double bond) or a salt thereof, preferably 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid or a salt thereof.
[Prior Art and Problems to Be Solved by the Invention]
The carbostyril derivatives represented by the above general formula (I) and the processes for production of said derivatives are described in Japanese Patent Publication No. 63-35623, etc. and the utility of said derivatives as an inhibitor for gastric ulcer is known. Further, the utility of the derivatives as a gastritis-treating agent is described in Japanese Patent Application Kokai (Laid-Open) No. 3-74329, and the processes for producing those compounds of said derivatives having an optical activity are described in Japanese Patent Application Kokai (Laid-Open) No. 3-145468.
Furthermore, inhibiting effect of compounds of the present invention on reactive oxygen metabolites is described in Japan. J. Pharmacol., Vol. 49, pp. 441-448 (1989), and the gastric mucous membrane protectability of the present invention compounds is described in Folia pharmacol. japon., Vol. 97, pp. 371-380 (1991).
Disturbances of intestinal mucous membrane include simple and primary ulcer of small intestine, nonspecific ulcer of colon, ulcerative colitis induced by nonspecific inflammations, Crohn's disease, etc., all of which appear owing to unknown causes. Disturbances of intestinal mucous membrane also appear owing to known causes such as infections, circular disturbances, collagen disease, radiations, medicines and the like. These disturbances of intestinal mucous membrane are generally hard to cure and, in some cases, surgical treatments are applied thereto. As the medicinal therapy for the disturbances, there are used adrenocortical steroids, Salazopyrin, immunosuppressive agents, etc. However, the steroidal drugs show side effects when administered in a large amount over a long period of time, and the immunosuppressive agents must be carefully used because of the very harmful side effects. Hence, it is desired to develop a medicine which is effective to the treatment of intractable disturbances of intestinal mucous membrane and which can be used safely over a long period of time.
Nonsteroidal anti-inflammatory drugs (hereinafter referred to as NSAID), which are widely used for various diseases attended by inflammations such as arthritis, chronic rheumatoid arthritis and the like, are known to give rise to disturbances of intestinal mucous membrane. The administration of these drugs must therefore be stopped in the middle in some cases. In patients of chronic rheumatoid arthritis, the treatment of rheumatism must be continued even when disturbances of intestinal mucous membrane have appeared, which requires the continued use of NSAID in such cases and poses a problem.
Under such a situation, various attempts were made to administer NSAID without incurring any disturbance of intestinal mucous membrane. For example, it was attempted to use a drug such as Sucralfate, Ranitidine (a histamine H2 blocker) or the like in combination with NSAID [e.g. Caldwell, J. R., et al., Am. J. Med., Vol. 83, pp. 74-82, 1987, and Ehsanullah, R. S. B. et al., Br. Med. J., Vol. 297, pp. 1017-1021, 1988]. However, no satisfactory result has been obtained yet.
SUMMARY OF THE INVENTION
The present inventors made an extensive study in order to find out a novel drug useful for prevention and treatment of disturbances of intestinal mucous membrane. As a result, the present inventors found that the carbostyril derivatives represented by the above general formula (I) or salts thereof, in particular, 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid or a salt thereof is useful for the prevention and treatment of disturbances of intestinal mucous membrane which are hard to cure. The finding has led to the completion of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
The present agent for preventing and treating disturbances of intestinal mucous membrane, when used by itself, is prepared in any form of ordinary pharmaceutical preparations each comprising a carbostyril derivative of general formula (I) or a salt thereof. Such preparations are prepared using diluents or excipients ordinarily employed, such as filler, extender, binder, wetting agent, disintegrating agent, surfactant, lubricant and the like. The pharmaceutical preparations can take various forms depending upon how they are administered for treatment, and typical examples of the forms are tablets, pills, a powder, a liquor, a suspension, an emulsion, granules, capsules, suppositories and injection preparations (solution, suspension, etc.).
For the purpose of shaping into the form of tablets, known carriers widely used in this field can be used. They are exemplified by excipients such as lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicic acid and the like; binders such as water, ethanol, propanel, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose, shellac, methyl cellulose, calcium phosphate, polyvinyl pyrrolidone and the like; disintegrating agents such as dried starch, sodium alginate, agar powder, laminalia powder, sodium hydrogencarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, monoglyceride of stearic acid, starch, lactose and the like; disintegration inhibitors such as sucrose, stearin, coconut butter, hydrogenated oil and the like; absorption accelerators such as quaternary ammonium base, sodium lauryl sulfate and the like; wetting agents such as glycerine, starch and the like; adsorbing agents such as starch, lactose, kaolin, bentonitc, colloidal silicic acid and the like; and lubricants such as purified talc, stearic acid salt, boric acid powder, polyethylene glycol and the like. If necessary, the tablets can further be coated with ordinary coating materials to make them into coated tablets such as sugar-coated tablets, gelatin-coated tablets, enteric-coated tablets, film-coated tablets, double-layer tablets, multiple-layer tablets and the like.
For the purpose of shaping into the form of pills, known carriers widely used in this field can be used. They are exemplified by excipients such as glucose, lactose, starch, coconut butter, hydrogenated vegetable oil, kaolin, talc and the like; binders such as powdered gum arabic, powdered tragacanth gum, gelatin, ethanol and the like; and disintegrating agents such as laminaria, agar and the like.
For the purpose of shaping into the form of suppositories, known carriers widely used in this field can be used. They are exemplified by polyethylene glycol, coconut butter, higher alcohols, higher alcohol esters, gelatin and semi-synthetic glycerides.
For the purpose of making into the form of injection preparations, solutions, emulsions or suspensions are prepared and are generally further sterilized and preferably made isotonic to the blood. In preparing the injection preparations in the form of solutions, emulsions or suspensions, any known carrier widely used in this field can be used. It is exemplified by water, ethanol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol and polyoxyethylene sorbitan fatty acid esters. The solutions, emulsions or suspensions may further contain sodium chloride, glucose or glycerine in an amount sufficient to make them isotonic to the blood. The solutions, emulsions or suspensions may furthermore contain a dissolving agent, a buffer solution, an analgesic agent, etc. all of ordinary use and, as necessary, a coloring agent, a preservative, a perfume, a seasoning agent, a sweetening agent and other medicines.
When the administration of NSAID must be continued for the treatment of diseases such as rheumatism and the like and therefore the present agent for preventing and treating disturbances of intestinal mucous membrane is used in combination with NSAID, it is preferable to administer the two medicines simultaneously. The two medicines may be administered as different medicines or as a mixed agent containing the two medicines.
The NSAID's with which the present agent is used in combination, are not particularly restricted and include all NSAID's widely used, such as Aspirin, Indomethacin, Diclofenac, Ibuprofen, Naproxen, Piroxicam, Mefenamic Acid, Flufenamic Acid, Floctafenine, Ethenzamide, Sodium salicylate, Diflunisal, Clofezone, Ketophenylbutazone, Phenylbutazone, Alclofenac, Alminoprofen, Ketoprofen, Flurbiprofen, Pranoprofen, Loxoprofen-Na, Tiaramide hydrochloride, Perisoxal citrate, Emorfazone, Acemetacin, Proglumetacin maleate, Bucolome and the like.
The amount of the present agent administered is appropriately determined depending upon the administration method, the age, sex and other conditions of patient, the degree of disease, etc. However, the preferable amount is generally 0.6-50 mg per kg of body weight per day in terms of the amount of carbostyril derivative of general formula (I) or salt thereof. The preferable amount of active ingredient in each application unit form is 10-1,000 mg when used in combination with NSAID. The present agent, when used in combination with NSAID, is used in an amount of generally 0.1-100 parts by weight per 1 part by weight of NSAID although the amount differs depending upon the kind of the NSAID used in combination. Therefore, when the present agent is used as a mixed agent containing both the present agent and NSAID, the desirable weight ratio of the present agent and NSAID is 0.01-10, preferably 0.1-10. That is, in the mixed agent containing both the present agent and NSAID, each administration unit form generally contains 10-1,000 mg of a carbostyril derivative of general formula (I) or a salt thereof and 1-1,000 mg of NSAID.
The amount of the carbostyril derivative of general formula (I) or the salt thereof contained in the present agent for preventing and treating disturbances of intestinal mucous membrane is not particularly restricted and can be selected from a wide range. However, the amount is generally 10-70% by weight, preferably, 10-50% by weight based on the total composition. When the present agent is used as a mixed agent containing both the present agent and NSAID, the total amount of the carbostyril derivative (I) or the salt thereof and NSAID is 10-90% by weight, preferably 30-70% by weight based on the total composition.
The present agent for preventing and treating disturbances of intestinal mucous membrane is useful for intractable disturbances of intestinal mucous membrane, particularly, ulcerative colitis and drug-induced disturbances of intestinal mucous membrane.
Next, the present agent for preventing and treating disturbances of intestinal mucous membrane is described specifically by showing examples of pharmaceutical preparations as well as pharmacological tests.
______________________________________                                    
Pharmaceutical Preparation 1                                              
______________________________________                                    
2-(4-Chlorobenzoylamino)-3-(2-quinolon-4-                                 
                             150 g                                        
yl)propionic acid                                                         
Avicel (a trademark for microcrystalline cellulose                        
                             40 g                                         
manufactured by Asahi Chemical Industry                                   
Co., Ltd.)                                                                
Corn starch                  30 g                                         
Magnesium stearate           2 g                                          
Hydroxypropylmethyl cellulose                                             
                             10 g                                         
Polyethylene glycol 6000     3 g                                          
Castor oil                   40 g                                         
Methanol                     40 g                                         
______________________________________
The compound of the present invention [2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid], Avicel, corn starch and magnesium stearate are mixed and ground. The mixture is shaped into tablets by using a punch having a diameter of 10 mm. The tablets are coated with a film coating agent consisting of hydroxypropylmethyl cellulose, polyethylene glycol 6000, castor oil and methanol to prepare film-coated tablets.
______________________________________                                    
Pharmaceutical Preparation 2                                              
______________________________________                                    
2-(4-Chlorobenzoylamino)-3-(2-quinolon-4-                                 
                           150 g                                          
yl)propionic acid                                                         
Citric acid                1.0 g                                          
Lactose                    33.5 g                                         
Calcium secondary phosphate                                               
                           70.0 g                                         
Pluronic F-68 (a trademark for a nonionic polyoxy-                        
                           30.0 g                                         
alkylene derivative of propylene glycol                                   
manufactured by BASF-Wyandotte Corp.)                                     
Sodium lauryl sulfate      15.0 g                                         
Polyvinylpyrrolidone       15.0 g                                         
Polyethylene glycol (Carbowax 1500)                                       
                           4.5 g                                          
Polyethylene glycol (Carbowax 6000)                                       
                           45.0 g                                         
Corn starch                30.0 g                                         
Dried sodium lauryl sulfate                                               
                           3.0 g                                          
Dried magnesium stearate   3.0 g                                          
Ethanol                    Necessary                                      
                           amount                                         
______________________________________
The compound of the present invention [2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid], citric acid, lactose, calcium secondary phosphate, Pluronic F-68 and sodium lauryl sulfate are mixed.
The mixture is sieved through a No. 60 screen and then made into wet granules by using an alcholic solution containing polyvinylpyrrolidone, Carbowax 1500 and Carbowax 6000. As necessary, ethanol is added to make the granules into a paste-like semi-solid. Corn starch is added thereto and the mixture is kneaded until granules of uniform size are formed. The granules are passed through a No. 10 screen, placed in a tray, and dried in an oven of 100° C. for 12-14 hours. The dried granules are sieved through a No. 16 screen. The granules which have passed through the screen, are mixed with dried sodium lauryl sulfate and dried magnesium stearate. The mixture is compressed into a desired shape by using a tablet machine.
The thus obtained tablets (each of which is to become the core portion of each multi-layer tablet obtained finally) are treated with a varnish at the surfaces. The varnish-treated surfaces are coated with talc so as to protect the surfaces from moisture absorption. Thereon is applied undercoating. Varnish coating is conducted sufficient times for oral administration. Undercoating and smooth coating are further applied to make the tablets completely spherical and smooth. Color coating is applied until a desired color is obtained. The resulting coated tablets are dried and then their surfaces are polished to obtain multi-layer tablets of uniform gloss.
______________________________________                                    
Pharmaceutical Preparation 3                                              
______________________________________                                    
2-(4-Chlorobenzoylamino)-3-(2-quinolon-4-                                 
                            150 g                                         
yl)propionic acid                                                         
Aspirin                     150 g                                         
Avicel                      40 g                                          
Corn starch                 30 g                                          
Magnesium stearate          2 g                                           
Hydroxypropylmethyl cellulose                                             
                            10 g                                          
Polyethylene glycol 6000    3 g                                           
Castor oil                  40 g                                          
Methanol                    40 g                                          
______________________________________
The above materials each of indicated amount are made into film-coated tablets by the same procedure as in Pharmaceutical Preparation 1.
______________________________________                                    
Pharmaceutical Preparation 4                                              
______________________________________                                    
2-(4-Chlorobenzoylamino)-3-(2-quinolon-4-                                 
                          150 g                                           
yl)propionic acid                                                         
Ibuprofen                 50.0 g                                          
Citric acid               1.0 g                                           
Lactose                   33.5 g                                          
Calcium secondary phosphate                                               
                          70.0 g                                          
Pluronic F-68             30.0 g                                          
Sodium lauryl sulfate     15.0 g                                          
Polyvinylpyrrolidone      15.0 g                                          
Polyethylene glycol (Carbowax 1500)                                       
                          4.5 g                                           
Polyethylene glycol (Carbowax 6000)                                       
                          45.0 g                                          
Corn starch               30.0 g                                          
Dried sodium lauryl sulfate                                               
                          3.0 g                                           
Dried magnesium stearate  3.0 g                                           
Ethanol                   Necessary                                       
                          amount                                          
______________________________________
The above materials each of indicated amount are made into tablets by the same procedure as in Pharmaceutical Preparation 2.
Pharmacological Test 1
Inhibitory effect on acetic acid-induced ulcerative colitis
2-(4-Chlorobenzoylamino)-3-(2-quinolon-4-yl)-propionic acid was used as a test compound, and its inhibitory effect on acetic acid-induced ulcerative colitis was examined.
Test method:
Male Wistar or Wistar/ST rats (10 week-old and weighing between 250 g and 300 g), which had been fasted for 24 hours, were subjected to laparotomy under anesthesia with ether. The cecum of each rat was taken out to the body surface; the lower portion of the cecum (i.e. the cecum portion connecting to the colon) was once ligated; and 2 ml of 5% acetic acid was injected into the large intestine at the portion just below the ligated cecum portion, via a 27G injection needle. Immediately after the acetic acid injection, 3 ml of air was injected to discharge acetic acid from the anus. Then, the ligation was released and the abdomen was sutured. After this operation, each rat was feeded as usual. 24 hours after operation, each rat was killed and the large intestine was extracted. The large intestine was cut longitudinally, opened and washed with a physiological saline solution to remove the contents, after which the washed large intestine was extended in a flat state. The lesion appearing in the mucous membrane of large intestine was observed by the naked eye and rated according to the following rating scale.
To each rat of each test group, the above-mentioned test compound dissolved in a solvent (a 0.5% carboxymethylcellulose aqueous solution) was orally administered twice a day (right after the acetic acid injection and 8 hours thereafter). To each rat of a reference group, only the above solvent was orally administered at the same timings as for the test compound administered to each test group. To each rat of a control group, nothing was administered.
Scale for rating the lesion appearing in mucous membrane of large intestine
Grade 0: no lesion.
Grade 1: hyperemia only.
Grade 2: hyperemia, or linear ulcer attended by no hypertrophy of intestinal wall.
Grade 3: linear ulcer attended by inflammation.
Grade 4: ulcer attended by two or more inflammations.
Grade 5: ulcer attended by two or more large inflammations, or one large lesion of at least 1 cm in size extending in the longitudinal direction of large intestine.
Grades 6 to 10: when the size of ulcer attended by inflammation exceeds 2 cm in the longitudinal direction of colon, grade increases by one (for example, from 6 to 7) per each 1 cm increase of said size.
Test results:
The results of the above test are shown in Table 1. As is clear from Table 1, the reference group, to which the above-mentioned solvent had been administered, showed high disturbances of mucous membrane of large intestine, as compared with the control group to which nothing was administered. Two times a day of oral administration of 30 mg/kg of the test compound significantly reduced the degree of acetic acid-induced ulcerative colitis.
              TABLE 1                                                     
______________________________________                                    
Inhibitory effect on acetic acid-induced ulcerative colitis               
           Dose of               Grade of lesion                          
           test compound                                                  
                        Number   of mocous                                
           (mg/kg,      of       membrane of                              
Group      p.o., b.i.d.)                                                  
                        rats     large intestine                          
______________________________________                                    
Control group                                                             
           --           8        0.0 ± 0.0                             
Reference group                                                           
           --           8        6.3 ± 0.6 ##                          
Test groups                                                               
A          7.5          8        5.3 ± 0.8 ##                          
B          15           8        5.3 ± 0.9 ##                          
C          30           8        2.6 ± 0.6 **                          
______________________________________
In Table 1, grade data are shown in the form of average value ± standard error. Test of significance was conducted by non-parametric Dunnett type multiple comparison.
## indicates significance over the control group at p<0.01, and ** indicates significance over the reference group at p<0.01.
Pharmacological Test 2
Inhibitory effect on NSAID-induced disturbances of intestinal mucous membrane
To each rat (male Wistar rat) of each test group were simultaneously administered orally an NSAID of an amount showing an analgesic effect [Aspirin (75 mg/kg), Ibuprofen (20 mg/kg), Naproxen (3 mg/kg) or Piroxicam (2 mg/kg)] and 30 mg/kg of a test compound [2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)-propionic acid]. They were administered twice a day for 1 week. Then, each rat was fasted for 24 hours and killed under anesthesia with ether, followed by extraction of alimentary canal from each rat. The alimentary canal was cut along the greater curvature and opened, and the surface of the mucous membrane was observed by the naked eye to rate the disturbances appearing thereon. To each rat of each control group was administered only a NSAID, and the same test as above was conducted. The results are shown in Table 2.
              TABLE 2                                                     
______________________________________                                    
           Degree of disturbances                                         
Test Groups  Duodenum    Jejunum  Ileum                                   
______________________________________                                    
Aspirin alone                                                             
             2.2 ± 1.0                                                 
                         0.4 ± 0.2                                     
                                  0.2 ± 0.2                            
Aspirin + test                                                            
             0 ± 0    0 ± 0 0 ± 0                                
compound                                                                  
Ibuprofen alone                                                           
             1.6 ± 0.9                                                 
                         --       0.4 ± 0.2                            
Ibuprefen + test                                                          
             1.2 ± 0.7                                                 
                         --       0 ± 0                                
compound                                                                  
Naproxen alone                                                            
             --          0.6 ± 0.2                                     
                                  --                                      
Naproxen + test                                                           
             --          0 ± 0 --                                      
compound                                                                  
Piroxicum alone                                                           
             --          0.4 ± 0.4                                     
                                  0.6 ± 0.2                            
Piroxicum + test                                                          
             --          0.2 ± 0.2                                     
                                  0 ± 0                                
compound                                                                  
______________________________________
The degrees of disturbances shown in Table 2 were rated using the following rating scale (grades 0 to (5) in accordance with the standard for rating of lesions of gastric mucosa by Adami et al. (Adami, E., et al.; Arch. int. Pharmacodyn. Ther., Vol. 147, Nos. 1-2, pp. 113-145, 1964).
Grade 0: no lesion.
Grade 1: hemorrhagic suffusion.
Grade 3: 5 or more small ulcers or one large ulcer.
Grade 4: many ulcers of marked size.
Grade 5: perforated ulcer.
As is clear from Table 2, all of the disturbances of mucous membranes of duodenum, jejunum and ileum, induced by NSAID were significantly reduced by the use of the present agent for preventing and treating intestinal mucous membrane, in combination with NSAID.

Claims (9)

I claim:
1. A method for preventing and treating disturbances of intestinal mucous membrane comprising administering to a patient in need thereof a pharmaceutical composition comprising, as the active ingredient, an effective amount for preventing and treating disturbances of intestinal mucous membrane of 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl) propionic acid or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
2. A method for preventing inflammatory disturbances of intestinal mucous membrane comprising administering to a patient in need thereof a pharmaceutical composition comprising, as the active ingredient, an effective amount for preventing inflammatory disturbances of intestinal mucous membrane of 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl) propionic acid or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
3. A method for preventing drug-induced disturbances of intestinal mucous membrane comprising administering to a patient in need thereof a pharmaceutical composition comprising, as the active ingredient, an effective amount for preventing drug-induced disturbances of intestinal mucous membrane of 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl) propionic acid or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
4. A method for preventing nonsteroidal anti-inflammatory drug-induced disturbances of intestinal mucous membrane comprising administering to a patient in need thereof a pharmaceutical composition comprising, as the active ingredient, an effective amount for preventing nonsteroidal anti-inflammatory drug-induced disturbances of intestinal mucous membrane of 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl) propionic acid or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
5. A method for preventing and treating ulcerative colitis comprising administering to a patient in need thereof a pharmaceutical composition comprising, as the active ingredient, an effective amount for preventing and treating ulcerative colitis of 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl) propionic acid or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
6. The method of claim 1, wherein the intestinal mucous membrane is jejunum or ileum mucous membrane and the amount of the active ingredient administered is an effective amount for preventing and treating disturbances of jejunum or ileum mucous membrane.
7. The method of claim 2, wherein the intestinal mucous membrane is jejunum or ileum mucous membrane and the amount of the active ingredient administered is an effective amount for preventing inflammatory disturbances of jejunum or ileum mucous membrane.
8. The method of claim 3, wherein the intestinal mucous membrane is jejunum or ileum mucous membrane and the amount of the active ingredient administered is an effective amount for preventing drug-induced disturbances of jejunum or ileum mucous membrane.
9. The method of claim 4, wherein the intestinal mucous membrane is jejunum or ileum mucous membrane and the amount of the active ingredient administered is an effective amount for preventing non-steroidal anti-inflammatory drug-induced disturbances of jejunum or ileum mucous membrane.
US08/256,372 1992-11-26 1993-11-19 Agent for preventing and treating disturbances of intestinal mucous membrane Expired - Fee Related US5576331A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP4-316852 1992-11-26
JP31685292 1992-11-26
JP5231353A JP2872546B2 (en) 1992-11-26 1993-09-17 Intestinal mucosal damage protective agent
JP5-231353 1993-09-17
PCT/JP1993/001700 WO1994012182A1 (en) 1992-11-26 1993-11-19 Agent for preventing and treating disturbances of intestinal mucous membrane

Publications (1)

Publication Number Publication Date
US5576331A true US5576331A (en) 1996-11-19

Family

ID=26529821

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/256,372 Expired - Fee Related US5576331A (en) 1992-11-26 1993-11-19 Agent for preventing and treating disturbances of intestinal mucous membrane

Country Status (9)

Country Link
US (1) US5576331A (en)
EP (1) EP0621782A1 (en)
JP (1) JP2872546B2 (en)
KR (1) KR0175345B1 (en)
CN (1) CN1040176C (en)
AU (1) AU668267B2 (en)
CA (1) CA2128094A1 (en)
MX (1) MX9307409A (en)
WO (1) WO1994012182A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821953B1 (en) 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
US20070112026A1 (en) * 2003-07-30 2007-05-17 Hisashi Nagamoto Carbostyril derivatives for accelerating salivation
US20070155787A1 (en) * 2004-01-21 2007-07-05 Yoshihiro Nishioka Amine salt of carbostyril derivative

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011026A1 (en) * 1993-10-21 1995-04-27 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivative for inhibiting production of interleukin-8
JPH0971532A (en) * 1995-09-06 1997-03-18 Otsuka Pharmaceut Co Ltd Carcinogenesis suppressing agent
AU5410998A (en) * 1996-12-16 1998-07-15 Otsuka Pharmaceutical Co., Ltd. Adp-ribosyltransferase inhibitor
JP2010024239A (en) * 1998-05-06 2010-02-04 Kowa Co Enterokinesis inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3324034A1 (en) * 1982-07-05 1984-01-05 Otsuka Pharmaceutical Co. Ltd., Tokyo CARBOSTYRIL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THEM
JPS6335623A (en) * 1986-07-30 1988-02-16 Hodogaya Chem Co Ltd Production method of polytetramethylene ether glycol
JPH0374329A (en) * 1989-08-14 1991-03-28 Otsuka Pharmaceut Co Ltd Remedy of gastritis
JPH03145468A (en) * 1989-10-28 1991-06-20 Otsuka Pharmaceut Co Ltd Production of carbostyryl derivative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS597168A (en) * 1982-07-05 1984-01-14 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS60142959A (en) * 1983-12-28 1985-07-29 Otsuka Pharmaceut Co Ltd Quinoline derivative
JPH01308258A (en) * 1989-04-27 1989-12-12 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPH06335623A (en) * 1993-05-28 1994-12-06 Dainippon Ink & Chem Inc Degassing membrane and degassing method

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3324034A1 (en) * 1982-07-05 1984-01-05 Otsuka Pharmaceutical Co. Ltd., Tokyo CARBOSTYRIL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THEM
US4578381A (en) * 1982-07-05 1986-03-25 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JPS6335623A (en) * 1986-07-30 1988-02-16 Hodogaya Chem Co Ltd Production method of polytetramethylene ether glycol
JPH0374329A (en) * 1989-08-14 1991-03-28 Otsuka Pharmaceut Co Ltd Remedy of gastritis
JPH03145468A (en) * 1989-10-28 1991-06-20 Otsuka Pharmaceut Co Ltd Production of carbostyryl derivative

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Effect of OPC-12759, a Novel Antiulcer Agent, on Chronic and Acute Experimental Gastric Ulcer, and Gastric Secretion in Rats", Yamasaki et al., Japan J. Pharmacol., vol. 49, No. 4, pp. 441-448, 1989.
"Effect of Rebamipide on Mucus Secretion by Endogenous Prostaglandin-independent Mechanism in Rat Gastric Mucosa", Ishihara et al., Arzneim.-Forsch./Drug Res., vol. 42, No. 12, pp. 1462-1466, 1992.
"Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine", Ehsanullah et al., British Medical Journal, vol. 297, pp. 1017-1021, Oct. 22, 1988.
"Protective effect of rebamipide (OPC-12759) on the gastric mucosa in rats and humans", Kawano et al., Folia pharmacol. japon., vol. 97, No. 6, pp. 371-380, 1991.
"Sucralfate Treatment of Nonsteroidal Anti-Inflammatory Drug-Induced Gastrointestinal Symptoms and Mucosal Damage", Caldwell et al., The American Journal of Medicine, vol. 83 (suppl. 3B), pp. 74-82, Sep. 28, 1987.
Effect of OPC 12759, a Novel Antiulcer Agent, on Chronic and Acute Experimental Gastric Ulcer, and Gastric Secretion in Rats , Yamasaki et al., Japan J. Pharmacol., vol. 49, No. 4, pp. 441 448, 1989. *
Effect of Rebamipide on Mucus Secretion by Endogenous Prostaglandin independent Mechanism in Rat Gastric Mucosa , Ishihara et al., Arzneim. Forsch./Drug Res., vol. 42, No. 12, pp. 1462 1466, 1992. *
Prevention of gastroduodenal damage induced by non steroidal anti inflammatory drugs: controlled trial of ranitidine , Ehsanullah et al., British Medical Journal, vol. 297, pp. 1017 1021, Oct. 22, 1988. *
Protective effect of rebamipide (OPC 12759) on the gastric mucosa in rats and humans , Kawano et al., Folia pharmacol. japon., vol. 97, No. 6, pp. 371 380, 1991. *
Sucralfate Treatment of Nonsteroidal Anti Inflammatory Drug Induced Gastrointestinal Symptoms and Mucosal Damage , Caldwell et al., The American Journal of Medicine, vol. 83 (suppl. 3B), pp. 74 82, Sep. 28, 1987. *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821953B1 (en) 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
US20050004036A1 (en) * 1999-12-16 2005-01-06 The University Of Southern California Methods for treating and preventing damage to mucosal tissue
US20070112026A1 (en) * 2003-07-30 2007-05-17 Hisashi Nagamoto Carbostyril derivatives for accelerating salivation
US7879877B2 (en) 2003-07-30 2011-02-01 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives for accelerating salivation
US20070155787A1 (en) * 2004-01-21 2007-07-05 Yoshihiro Nishioka Amine salt of carbostyril derivative
US7732611B2 (en) * 2004-01-21 2010-06-08 Otsuka Pharmaceutical Co., Ltd. Amine salt of carbostyril derivative
US20100210684A1 (en) * 2004-01-21 2010-08-19 Otsuka Pharmaceutical Co., Ltd. Amine salt of carbostyril derivative
US8222276B2 (en) 2004-01-21 2012-07-17 Otsuka Pharmaceutical Co., Ltd. Amine salt of carbostyril derivative

Also Published As

Publication number Publication date
CN1095593A (en) 1994-11-30
CA2128094A1 (en) 1994-06-09
CN1040176C (en) 1998-10-14
AU668267B2 (en) 1996-04-26
AU5534094A (en) 1994-06-22
KR950700064A (en) 1995-01-16
KR0175345B1 (en) 1999-02-18
JPH06211662A (en) 1994-08-02
EP0621782A1 (en) 1994-11-02
WO1994012182A1 (en) 1994-06-09
JP2872546B2 (en) 1999-03-17
MX9307409A (en) 1994-07-29

Similar Documents

Publication Publication Date Title
JP4183746B2 (en) Novel stable galenic preparation containing acid labile benzimidazole and method for producing the same
US5601843A (en) Pharmaceutical tablet composition
US5593696A (en) Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
KR100475759B1 (en) Sustained release ranolazine formulations
US5213807A (en) Pharmaceutical composition containing ibuprofen and a prostaglandin
DK170922B1 (en) Cefaclor formulation with long lasting effect
KR101298788B1 (en) A combined formulation with improved stability
US20110008426A1 (en) Modified release pharmaceutical compositions comprising mycophenolate and processes thereof
HU199677B (en) Process for producing retard pharmaceutical composition
JPH11505542A (en) Triphasic pharmaceutical formulation with constant and controlled release of amorphous active ingredient for once daily dosing
US5576331A (en) Agent for preventing and treating disturbances of intestinal mucous membrane
JPH1036269A (en) Drug for reducing dysmenorrhoe and/or syndrome before menstruation
WO2017084680A1 (en) Pharmaceutical composition containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
PT97550B (en) PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION CONTAINING IBUPROFEN, AND A PROSTAGLANDINE
US6100300A (en) Metformin formulations and method for treating intermittent claudication employing same
US5480891A (en) Method for treating diabetes mellitus
US20020102309A1 (en) Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
US20240024263A1 (en) Methods of administering gamma-hydroxybutyrate compositions with divalproex sodium
US20040146556A1 (en) Oral extended release tablets and methods of making and using the same
KR100192534B1 (en) Agent for increasing somatostatin or for inhibiting decrease of somatostatin
KR20010041460A (en) Pellets having a core coated with a lipid lowering agent and a polymer
JP2812998B2 (en) Gastritis treatment
WO2000078307A1 (en) Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
WO1997040828A1 (en) Rapid-release s1452 tablets
US20040185092A1 (en) Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use

Legal Events

Date Code Title Description
AS Assignment

Owner name: OTSUKA PHARMACEUTICAL CO., LTD.

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YAMASAKI, KATSUYA;SAKURAI, KAZUSHI;AKIYAMA, KAZUE;REEL/FRAME:007155/0793

Effective date: 19940630

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 20001119

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载